To reconcile these discrepancies, and based on previous findings showing that PR activation of signaling cascades and proliferative effects in breast cancer may occur via PR crosstalk with ERα[3,51,52], we reasoned that the assembly of the PR/AP-1 complex might be involved in the response to therapy, which currently targets ERα. The gene discussed is JUN; the disease is breast cancer.